MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from term loan,
net of issuance...
$96,257K
Proceeds from exercise of
common stock options...
$5,681K
Proceeds from milestone
obligations met under...
$2,660K
Maturities of short-term
investments,...
$307,000K
Net cash and cash
equivalents provided by...
$104,598K
Net cash and cash
equivalents provided by...
$56,768K
Canceled cashflow
$250,232K
Net decrease in cash
and cash...
-$9,500K
Canceled cashflow
$161,366K
Stock-based compensation
expense
$22,095K
Accounts payable and
accrued liabilities
$18,881K
Provision for inventory
reserve
$2,160K
Depreciation and
amortization expense
$1,367K
Prepaid expenses and
other assets
-$656K
Other non-cash items
-$337K
Purchases of short-term
investments,...
$242,033K
Payments of milestone
obligations under license...
$7,860K
Purchases of property and
equipment
$339K
Net cash and cash
equivalents (used in)...
-$170,866K
Canceled cashflow
$45,496K
Total revenue
$84,278K
Interest income
$10,669K
Income tax (benefit)
expense
-$80K
Net (loss) income
-$171,298K
Canceled cashflow
$95,027K
Inventories
$21,986K
Accounts receivable
$17,205K
Accretion on investments,
net of amortization
$5,523K
Contract liability
-$350K
Total segment
operating...
$176,087K
Total segment
operating...
$29,352K
Total segment
operating...
$22,095K
Total segment
operating expenses-Cost...
$20,423K
Total segment
operating...
$5,342K
Total segment
operating...
$5,315K
Total segment
operating...
$4,334K
Interest expense
$2,599K
Total segment
operating expenses-Other...
$778K
Back
Back
Cash Flow
source: myfinsight.com
ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc. (SPRY)